Chipscreen(SH:688321) Xin Lang Zheng Quan·2025-10-31 12:27Core Viewpoint - Microchip Biotech announced a share buyback plan with a total amount between 10 million and 15 million yuan, with a maximum buyback price of 47.46 yuan per share, which is 53.74% higher than the current price of 30.87 yuan [1] Group 1: Company Overview - Microchip Biotech, established on March 21, 2001, and listed on August 12, 2019, is located in Shenzhen, Guangdong Province [1] - The company focuses on providing affordable, urgently needed innovative molecular entity drugs for patients, with main business revenue composition: 97.80% from product sales, 1.81% from other (supplementary), 0.27% from technology licensing, and 0.13% from other sources [1] - The company belongs to the pharmaceutical and biotechnology industry, specifically in chemical pharmaceuticals and formulations, and is involved in concepts such as AI medicine, anti-cancer drugs, biopharmaceuticals, and innovative drugs [1] Group 2: Financial Performance - As of September 30, 2025, Microchip Biotech achieved operating revenue of 674 million yuan, a year-on-year increase of 40.12%, and a net profit attributable to shareholders of 70.77 million yuan, a year-on-year increase of 238.53% [2] - The number of shareholders increased to 24,400, a rise of 25.25%, while the average circulating shares per person decreased by 20.16% to 16,681 shares [2] - As of September 30, 2025, Hong Kong Central Clearing Limited became the sixth largest circulating shareholder, holding 10.2021 million shares as a new shareholder [2]